Elevation Oncology, Inc. (ELEV)
| Market Cap | 139.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.31M |
| Shares Out | 23.23M |
| EPS (ttm) | -4.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33 |
| Open | 6.26 |
| Previous Close | 6.00 |
| Day's Range | 5.85 - 6.26 |
| 52-Week Range | 4.15 - 16.22 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.00 (+233.3%) |
| Earnings Date | Nov 11, 2021 |
About ELEV
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ELEV stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 233.33% from the latest price.
News
Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 Milestones
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...
Elevation Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...
Elevation Oncology to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology Reports Third Quarter 2021 Financial Results
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer
NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology's Seribantumab Included as Part of a Case Series Presentation at the Australasian Gastro-Intestina...
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 7, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology Reports Second Quarter 2021 Financial Results
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology to Present at the 12th Annual Wedbush PacGrow Healthcare Conference
NEW YORK, Aug. 4, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...
Elevation Oncology Announces Pricing of Initial Public Offering
NEW YORK, June 24, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...